Xadago is intended to be used as an add-on treatment for patients with Parkinson’s disease who are already taking a combination therapy of levodopa and carbidopa for the condition, yet still experiencing “off” episodes.
“Off episodes” occur when a patient’s medication is not working properly, resulting in heightened Parkinson’s symptoms like tremors or difficulty walking, according to the FDA.
“Xadago as an add-on to levodopa/carbidopa provided a significant reduction in off time and a significant increase in ON time without troublesome dyskinesia in [Parkinson’s] patients experiencing motor fluctuations,” Warren Olanow, MD, a professor of neurology and neuroscience at the Mount Sinai School of Medicine in New York City, said in a statement.
More articles on supply chain:
96% of older Americans want Medicare to negotiate drug costs: 4 survey findings
FDA granted 99% of applications for access to unapproved drugs in FY 2016
FDA warns of safety risks with Abbott’s dissolving stent: 5 takeaways
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
